Scholar Rock Holding Corp (SRRK)
26.49
-1.01
(-3.67%)
USD |
NASDAQ |
Nov 15, 16:00
26.50
+0.01
(+0.04%)
After-Hours: 20:00
Scholar Rock Research and Development Expense (TTM): 169.15M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 169.15M |
| June 30, 2024 | 150.76M |
| March 31, 2024 | 135.26M |
| December 31, 2023 | 121.90M |
| September 30, 2023 | 116.55M |
| June 30, 2023 | 119.61M |
| March 31, 2023 | 124.81M |
| December 31, 2022 | 124.44M |
| September 30, 2022 | 123.88M |
| June 30, 2022 | 121.76M |
| March 31, 2022 | 115.28M |
| December 31, 2021 | 108.47M |
| September 30, 2021 | 101.20M |
| June 30, 2021 | 88.32M |
| Date | Value |
|---|---|
| March 31, 2021 | 79.71M |
| December 31, 2020 | 74.06M |
| September 30, 2020 | 66.35M |
| June 30, 2020 | 63.66M |
| March 31, 2020 | 60.38M |
| December 31, 2019 | 54.22M |
| September 30, 2019 | 50.28M |
| June 30, 2019 | 42.64M |
| March 31, 2019 | 40.35M |
| December 31, 2018 | 36.31M |
| September 30, 2018 | 33.07M |
| June 30, 2018 | 29.79M |
| March 31, 2018 | 23.08M |
| December 31, 2017 | 19.94M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
54.22M
Minimum
Dec 2019
169.15M
Maximum
Sep 2024
105.99M
Average
115.92M
Median
Research and Development Expense (TTM) Benchmarks
| Cytokinetics Inc | -- |
| Regeneron Pharmaceuticals Inc | 4.897B |
| Ocugen Inc | 33.34M |
| Mirum Pharmaceuticals Inc | 121.95M |
| NeuroBo Pharmaceuticals Inc | 21.36M |